USPTO Examiner PROSSER ALISSA J - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19182602Cosmetic FormulationApril 2025August 2025Allow410NoNo
18428005COMPLEXES OF WHEY PROTEIN MICELLES AND PECTIN AND BODY MUSCLE PROTEIN SYNTHESISJanuary 2024March 2026Abandon2520NoYes
18525495SOLID HAND AND BODY LOTION PELLETSNovember 2023August 2024Abandon810NoNo
18504280AQUEOUS ORAL COMPOSITIONS INCLUDING POTASSIUM CHLORIDENovember 2023December 2025Allow2530NoNo
18260963PREPARATION OF A TINTED COSMETIC COMPOSITIONJuly 2023February 2026Abandon3101NoNo
18199345COMPOSITE PARTICLES, METHOD OF PRODUCING COMPOSITE PARTICLES AND DRY POWDER OF COMPOSITE PARTICLES, SKIN APPLICATION COMPOSITION AND METHOD OF PRODUCING THE SKIN APPLICATION COMPOSITIONMay 2023December 2025Abandon3111NoNo
18139095TABLET CONTAINING VALSARTAN AND SACUBITRILApril 2023December 2024Abandon2011YesNo
18302726DELIVERY OF COSMETIC AGENTS, COMPOSITIONS AND USE THEREOFApril 2023April 2025Abandon2420NoNo
18026633MOISTURIZING ANTIBACTERIAL COMPOSITIONMarch 2023May 2025Abandon2641NoNo
18026658MOISTURIZING ANTIBACTERIAL COMPOSITIONMarch 2023May 2025Abandon2641NoNo
18024281SUNSCREEN OR DAILY CARE COMPOSITION COMPRISING MICRONIZED TRIS-BIPHENYL TRIAZINEMarch 2023December 2025Abandon3301NoNo
18017734COSMETIC MASK FOR IMPROVING APPEARANCE OF SKINJanuary 2023November 2024Abandon2121NoNo
18155677GADUSOL-CONTAINING SUNSCREEN FORMULATIONSJanuary 2023September 2024Abandon2021YesNo
17928327A PERSONAL CARE COMPOSITION BASED ON TITANIUM OXIDE AND A CROSSPOLYMER OF ADIPIC ACID AND NEOPENTYL GLYCOLNovember 2022March 2026Abandon3911NoNo
18057777PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS BLENDS OF WATER-MISCIBLE, PHARMACEUTICALLY ACCEPTABLE SOLVENTSNovember 2022November 2025Abandon3531NoYes
17975284ANHYDROUS COSMETIC CONCEALER COMPOSITIONS HAVING LOW FILLER LEVELSOctober 2022August 2025Abandon3451NoNo
17823939GADUSOL-CONTAINING SUNSCREEN FORMULATIONSAugust 2022October 2025Abandon3801NoNo
17865229Exosome-based Skincare ProductJuly 2022November 2023Allow1610NoNo
17791703COSMETIC COMPOSITIONJuly 2022February 2026Abandon4311NoNo
17848269SALINE-BASED NASAL TREATMENT COMPOSITIONJune 2022September 2023Allow1510NoNo
17842609Sunscreen CompositionJune 2022February 2025Abandon3230NoNo
17777726HAIR CARE COMPOSITIONMay 2022October 2025Abandon4111NoNo
17773611TREATMENT OF TOOTH DECAY USING A CHEWING GUM COMPOSITION COMPRISING CANNABINOIDSMay 2022June 2025Abandon3810NoNo
17660499AQUEOUS ORAL COMPOSITIONS INCLUDING POTASSIUM CHLORIDEApril 2022November 2023Abandon1910NoNo
17770963Fighting Against Varroa Parasite in Beekeeping Using a Natural Formulation Comprising Essential Oils and Wood VinegarApril 2022April 2025Allow3620NoNo
17764625PRESSURE-SENSITIVE ADHESIVE MATRIX AND PATCHMarch 2022March 2026Abandon4731NoNo
17694367HYBRID NAIL COATING SYSTEMS AND METHODS OF THEIR USEMarch 2022July 2024Abandon2820NoNo
17692686ANHYDROUS SKIN CARE COMPOSITION COMPRISING RETINOL AND/OR BAKUCHIOLMarch 2022December 2025Abandon4551NoNo
17649674COSMETIC COMPOSITIONSFebruary 2022September 2024Abandon3120NoNo
17631853PHOTOCURABLE COMPOSITIONJanuary 2022September 2025Abandon4311NoNo
17581322BIODEGRADABLE POLYMER MICROPARTICLE FOR FILLER, MANUFACTURING METHOD THEREOF, FREEZE-DRIED BODY INCLUDING THE SAME, AND FILLER INJECTION INCLUDING THE SAMEJanuary 2022December 2022Allow1111NoNo
17626116SOLID HAIR CONDITIONING COMPOSITIONSJanuary 2022June 2025Abandon4221NoNo
17624287COMPOSITION FOR TREATING AND PREVENTING BACTERIAL GROWTH ON A SUBSTRATEDecember 2021October 2025Abandon4621NoNo
17565441WATER-SOLUBILIZED MIXTURE OF GINSENOSIDE COMPOUND K AND METHOD OF WATERSOLUBILIZING GINSENOSIDE COMPOUND KDecember 2021November 2023Abandon2210NoNo
17559447Flexible Gelatin Sealant Dressing with Reactive ComponentsDecember 2021June 2024Abandon2930NoNo
17549131HEMOSTATIC COMPOSITIONS AND METHODS OF MAKING THEREOFDecember 2021January 2024Allow2520NoNo
17543503CATALYTIC SYSTEMS INCLUDING A PEROXIDE FOR DELIVERY OF OXYGEN TO SKIN AND RELATED METHODS OF USEDecember 2021December 2025Abandon4860YesNo
17616511PARTICLE-CONTAINING COMPOSITIONDecember 2021August 2023Abandon2121YesNo
17608937TOPICAL COMPOSITIONSNovember 2021March 2025Abandon4111NoNo
17607642DENTAL ROOT CANAL FILLING MATERIAL COMPOSITIONOctober 2021December 2025Abandon4921NoNo
17607654HAIR DYEING METHODOctober 2021January 2025Abandon3810NoNo
17606443NUTRIENT SOLUTION FORMULA FOR INHIBITING GREEN ALGAEOctober 2021October 2024Allow3610NoNo
17604638Antifungal WallboardsOctober 2021March 2025Abandon4111NoNo
17485891STABLE LIQUID COMPOSITIONS OF PEMETREXEDSeptember 2021July 2024Abandon3321NoNo
17482003Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic PlasticitySeptember 2021May 2024Abandon3230NoNo
17441869SURFACE-MODIFIED DOPED TITANIUM DIOXIDE NANOPARTICLES AND USESSeptember 2021August 2025Abandon4721NoNo
17476716METHOD FOR DRY POWDER COATING CAPSULESSeptember 2021September 2023Abandon2401NoNo
17440124EXTENDED RELEASE COMPOSITION OF TOFACITINIBSeptember 2021December 2024Abandon3901NoNo
17438735COMPOSITIONS AND METHODS FOR 3D PRINTED FIBROUS SCAFFOLDS WITH ANTIMICROBIAL PROPERTIES INCORPORATING GRAPHENE OXIDE AND POLY(E-CAPROLACTONE)September 2021February 2025Abandon4111NoNo
17433919PATCHAugust 2021February 2025Abandon4120NoNo
17264152GINKGO BILOBA LEAVE EXTRACT CAPSULE AND PREPARATION METHOD THEREFORAugust 2021May 2025Allow5121NoNo
17433424ANTIMICROBIAL DRESSING, DRESSING COMPONENTS, AND METHODSAugust 2021April 2025Abandon4421NoNo
17401722HAIR TREATMENT COMPOSITIONS PROVIDING BRIGHTENING AND SHINEAugust 2021February 2026Abandon5441YesYes
17400396BIOFLAVONOID IMPREGNATED MATERIALSAugust 2021October 2023Abandon2611NoNo
17387812Composition for treating diabetes based on traditional Chinese medicine nutritional therapy and application thereofJuly 2021June 2025Abandon4721NoNo
17425969A COMPOSITE AND A METHOD OF PREPARING THE SAMEJuly 2021November 2025Abandon5241NoNo
17421916RAPIDLY DISINTEGRATING ORAL TABLETJuly 2021October 2024Abandon3901NoNo
17420182SUSTAINED-RELEASE INJECTION FORMULATION COMPRISING CONJUGATE OF POLY-L-LACTIC ACID FILLER AND HYALURONIC ACID FILLER AND BIOACTIVE MATERIALS, AND PREPARATION METHOD THEREOFJuly 2021June 2024Allow3610NoNo
17364081BIODEGRADABLE SINGLE-PHASE COHESIVE HYDROGELSJune 2021July 2024Abandon3721NoNo
17350268TABLET CONTAINING FERRIC CITRATEJune 2021May 2023Abandon2301NoNo
17413390BERBERINE/MINERALIZED COLLAGEN-BASED COMPOSITE MEMBRANE AND PREPARATION METHOD AND APPLICATION THEREOFJune 2021April 2024Allow3410NoNo
17312979SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ADMINISTRATION OF MESALAZINE OR DERIVATIVES THEREOFJune 2021February 2025Abandon4411NoNo
17315557USE OF HYDROXYAPATITE AS A CARRIER OF BIOACTIVE SUBSTANCES FOR TREATING VASCULAR DISEASES IN PLANTSMay 2021June 2023Allow2600NoNo
17302428ANTIVIRAL PREPARATION FOR TREATING HUMAN SKINMay 2021October 2023Abandon2911NoNo
17290670HAIR COSMETIC AND HAIR TREATMENT METHOD USING SAMEApril 2021December 2024Abandon4321NoNo
17285709METHOD FOR PRODUCING COATING FILMApril 2021July 2024Abandon3901NoNo
17218797PRESERVATIVE SYSTEMMarch 2021June 2025Abandon5181NoNo
17216128Skin Protecting Cosmetic Concealer OintmentMarch 2021July 2024Abandon4030NoNo
17189768Mattifying Cosmetic CompositionsMarch 2021February 2023Abandon2410NoNo
17187882Delivery Of Cosmetic Agents, Compositions And Use ThereofMarch 2021February 2024Abandon3631NoNo
17270604Folded Porous Ingrowth Features for Medical ImplantsFebruary 2021June 2024Abandon4001NoNo
17268620Oil-Based Solid CosmeticFebruary 2021February 2025Allow4861YesNo
17167282BIOFLAVONOID IMPREGNATED MATERIALSFebruary 2021February 2025Abandon4941NoNo
17159574MASCARA COMPOSITION AND METHOD OF USEJanuary 2021June 2024Abandon4131NoNo
17262436COMPOSITIONS AND RELATED METHODS FOR AGRICULTUREJanuary 2021May 2025Abandon5220NoYes
17154842SKINCARE COMPOSITIONS INCLUDING ZINC OXIDEJanuary 2021August 2022Allow1910NoNo
17250410Personal Care Compositions and Methods for the SameJanuary 2021February 2025Abandon4831NoNo
17146356METHOD FOR PROMOTING HOMEOSTASIS IN THE SKINJanuary 2021June 2023Abandon2920NoNo
17144533METHOD AND SYSTEM FOR REMOVING MAKEUPJanuary 2021April 2025Abandon5181NoNo
17137370EYELASH LIQUID EYELINERDecember 2020April 2022Allow1500NoNo
17251015FLOWABLE CANNABINOID COMPOSITIONS HAVING HIGH EFFECTIVE CONCENTRATIONSDecember 2020March 2024Abandon3910NoNo
16972431COMPOSITION FOR DYEINGDecember 2020June 2023Abandon3021YesNo
16981104MASSAGE CANDLE CONTAINING CANNABIDIOL OR ESSENTIAL OILDecember 2020December 2024Abandon5140NoNo
16972219OIL-IN-WATER TYPE EMULSION COSMETIC USING PARTIALLY CROSSLINKED OR CROSSLINKED DIMETHYLPOLYSILOXANEDecember 2020June 2024Abandon4240NoNo
17109160PUMPKIN SEED PROTEIN NANOPARTICLES, METHODS FOR PREPARING AND USING THEREOFDecember 2020June 2022Allow1810NoNo
16952370ALCOHOL-BASED SPRAYABLE GEL WITH YIELD POINTNovember 2020November 2023Abandon3630NoNo
16952083METHOD FOR PRODUCING SOLID POWDER COSMETICNovember 2020May 2023Abandon3030NoNo
16766966METHOD FOR PRODUCING COSMETIC COMPOSITION COMPRISING NATURAL PLANT AND COSMETIC COMPOSITION PRODUCED THEREBYNovember 2020June 2025Abandon6041YesNo
16949647MASCARA FORMULATIONNovember 2020December 2022Abandon2510NoNo
17091166SKIN CARE COMPOSITIONS AND METHODS FOR MAKING THE SAMENovember 2020January 2023Abandon2711NoNo
17048432POWDEROUS COMPOSITION COMPRISING CAROTENOID AND/OR DERIVATIVE THEREOF, D-GLYCOSE OLIGOMERS AND MODIFIED POLYSACCHARIDE AS WELL AS FOOD, FEED OR PERSONAL CARE FORMULATION COMPRISING THE COMPOSITIONOctober 2020May 2024Abandon4320NoNo
17046860THICK WATER-BASED COSMETICOctober 2020July 2024Abandon4540YesNo
17060191Sincalide FormulationsOctober 2020July 2022Abandon2110NoNo
17038943HYDRATING NO-RINSE COMPOSITION FOR MAKEUP REMOVALSeptember 2020June 2025Abandon5651YesNo
17031546ANTIBACTERIAL ACTIVITY BY MG COMPLEX IN DEODORANT EMULSION FOR AEROSOLS, DEODORANT INCLUDING THE SAME AND USE OF THE DEODORANTSeptember 2020July 2022Abandon2110NoNo
170402083D PRINTING COMPOSITION FOR BIOMATERIALSSeptember 2020December 2025Abandon6031YesNo
16980435COMPOSITION FOR PURIFICATION OF BIOFLUIDSSeptember 2020October 2024Abandon4921YesNo
16979375WATER-RESISTANT COSMETIC COMPOSITIONSeptember 2020August 2023Abandon3641NoNo
17013541NAIL COATING REMOVER CREAM MASK AND THE METHOD OF USING THEREOFSeptember 2020September 2022Abandon2431YesNo
17010121COMPOSITE PARTICLES, METHOD OF PRODUCING COMPOSITE PARTICLES AND DRY POWDER OF COMPOSITE PARTICLES, SKIN APPLICATION COMPOSITION AND METHOD OF PRODUCING THE SKIN APPLICATION COMPOSITIONSeptember 2020April 2024Abandon4361YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PROSSER, ALISSA J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
41
Examiner Affirmed
35
(85.4%)
Examiner Reversed
6
(14.6%)
Reversal Percentile
26.7%
Lower than average

What This Means

With a 14.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
103
Allowed After Appeal Filing
9
(8.7%)
Not Allowed After Appeal Filing
94
(91.3%)
Filing Benefit Percentile
12.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 8.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PROSSER, ALISSA J - Prosecution Strategy Guide

Executive Summary

Examiner PROSSER, ALISSA J works in Art Unit 1619 and has examined 483 patent applications in our dataset. With an allowance rate of 16.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner PROSSER, ALISSA J's allowance rate of 16.4% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PROSSER, ALISSA J receive 3.22 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PROSSER, ALISSA J is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +13.8% benefit to allowance rate for applications examined by PROSSER, ALISSA J. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 3.2% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 11.1% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 32.8% of appeals filed. This is in the 4% percentile among all examiners. Of these withdrawals, 45.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 84.8% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.